Protagonist Therapeutics Inc

NASDAQ:PTGX   3:58:50 PM EDT
26.10
-0.45 (-1.70%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)1.15B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$1.5 Million
Adjusted EPS-$0.54
See more estimates
10-Day MA$26.37
50-Day MA$27.17
200-Day MA$22.10
See more pivots

Protagonist Therapeutics, Inc. Stock, NASDAQ:PTGX

7707 Gateway Boulevard, Suite 140, Newark, California 94560-1160
Phone: +1.510.474.0170
Number of Employees: 73

Description

Protagonist Therapeutics, Inc. engages in the research and development of novel constrained peptide-based drug candidates that address significant unmet medical needs. Its product pipeline include PTG-300, PTG-200, and PN-943 The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.